Trusted News Discovery Since 2008
{{/content}}
'COVAXIN' demonstrated efficacy of 80.6% in Phase 3 clinical trial: Bharat Biotech
Video Credit: ANI
Published on March 3, 2021 - Duration: 01:42s
'COVAXIN' demonstrated efficacy of 80.6% in Phase 3 clinical trial: Bharat Biotech
Bharat Biotech's COVID-19 vaccine, 'COVAXIN' has demonstrated an interim vaccine efficacy of 80.6% in its Phase 3 clinical trial.
"Today is an important day for us, country and Indian science.
COVAXIN has demonstrated an interim vaccine efficacy of around 80.6% in its Phase 3 clinical trial.
The trials involved 25,800 subjects, the largest ever conducted in India, in partnership with ICMR," Bharat Biotech chairman Dr Krishna Ella.
You are here
💡 newsR Knowledge: Other News Mentions
COVID-19
Contagious disease caused by SARS-CoV-2
London Irish, Wasps and Worcester went out of business needing to repay more than £30m of Covid relief loans, a National Audit Office report says.
Credit: BBC Sport - Published 1 week ago
Related news from verified sources
Bharat Biotech announced the phase 3 results of its coronavirus vaccine ‘Covaxin’on Wednesday claiming the shots have demonstrated an interim clinical...
on March 3, 2021 • Zee News
prestigious medical journal The Lancet has now published Phase 2 clinical trial results of Bharat Biotech's Covaxin. "Due to the difference in dosing regimens...
on March 9, 2021 • IndiaTimes
Related videos from verified sources
Watch: Harsh Vardhan takes 2nd dose of Covaxin, says 7 more vaccines in trials 05:01
Video credit: HT Digital Content - Published on March 30, 2021
‘India doing its best…’: Costa Rica, Paraguay request COVAXIN supply 03:49
Video credit: HT Digital Content - Published on March 18, 2021
Ambassador of Paraguay to India requests 'COVAXIN' supply 02:20
Video credit: ANI - Published on March 17, 2021